| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3392084 | Transplant Immunology | 2014 | 5 Pages |
Abstract
In conclusion, data indicate that EVL plus reduced TAC is not superior to EVL plus reduced CSA regarding treatment failure and kidney function. However, compared with EVL plus reduced CSA, EVL plus reduced TAC seems to reduce cardiac rejections.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Uwe Fuchs, Armin Zittermann, Stephan M. Ensminger, Uwe Schulz, Jan F. Gummert,